Milestone Pharmaceuticals (MIST) News Today $2.04 -0.02 (-0.97%) Closing price 02/21/2025 04:00 PM EasternExtended Trading$2.10 +0.06 (+3.19%) As of 02/21/2025 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Milestone receives notice of allawance from USPTO on etripamil nasal sprayFebruary 19 at 7:25 PM | markets.businessinsider.comMilestone® Pharmaceuticals Notice of Allowance on New U.S. Patent for EtripamilFebruary 19 at 8:00 AM | globenewswire.comShort Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Declines By 27.9%Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of a significant drop in short interest in January. As of January 31st, there was short interest totalling 481,400 shares, a drop of 27.9% from the January 15th total of 667,900 shares. Based on an average trading volume of 612,900 shares, the short-interest ratio is presently 0.8 days.February 15, 2025 | marketbeat.comMilestone Pharmaceuticals to host Commercial Launch Plan investor eventFebruary 11, 2025 | markets.businessinsider.comMilestone Pharmaceuticals to Host Commercial Launch Plan Investor Event in New York on February 25, 2025February 11, 2025 | globenewswire.comLoss-Making Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Expected To Breakeven In The Medium-TermFebruary 3, 2025 | finance.yahoo.comWhat is HC Wainwright's Estimate for MIST Q1 Earnings?Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Stock analysts at HC Wainwright lowered their Q1 2025 earnings estimates for shares of Milestone Pharmaceuticals in a report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post eaJanuary 29, 2025 | marketbeat.comMilestone Pharmaceuticals provides 2025 corporate outlookJanuary 29, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Provides 2025 Corporate Outlook and Will Host Investor Event on February 25 in NYCJanuary 28, 2025 | globenewswire.comFY2029 Earnings Estimate for MIST Issued By HC WainwrightMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Equities research analysts at HC Wainwright issued their FY2029 earnings per share (EPS) estimates for Milestone Pharmaceuticals in a research report issued to clients and investors on Monday, January 27th. HC Wainwright analyst P. TrucJanuary 28, 2025 | marketbeat.comH.C. Wainwright maintains $25 target on Milestone sharesJanuary 27, 2025 | msn.comMilestone Pharmaceuticals' (MIST) "Buy" Rating Reiterated at HC WainwrightHC Wainwright reaffirmed a "buy" rating and issued a $25.00 target price on shares of Milestone Pharmaceuticals in a research report on Monday.January 27, 2025 | marketbeat.comMilestone Pharmaceuticals reports inducement grants under Nasdaq listing ruleJanuary 7, 2025 | markets.businessinsider.comMilestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 7, 2025 | globenewswire.comMilestone Pharmaceuticals (NASDAQ:MIST) Trading Down 8.1% - Time to Sell?Milestone Pharmaceuticals (NASDAQ:MIST) Trading Down 8.1% - Should You Sell?January 3, 2025 | marketbeat.comMilestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare ConferenceNovember 25, 2024 | markets.businessinsider.comMilestone Pharmaceuticals’ CARDAMYST: A Promising Buy with FDA Decision and Phase 3 Trial on HorizonNovember 15, 2024 | markets.businessinsider.comMilestone Pharmaceuticals (MIST) Gets a Buy from Piper SandlerNovember 14, 2024 | markets.businessinsider.comMilestone Pharmaceuticals reports Q3 EPS (14c) vs. (35c) last yearNovember 13, 2024 | markets.businessinsider.comMilestone Pharmaceuticals files $250M mixed securities shelfNovember 13, 2024 | markets.businessinsider.comMilestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateNovember 12, 2024 | globenewswire.comMilestone Pharmaceuticals (MIST) Receives a Buy from TD CowenOctober 21, 2024 | markets.businessinsider.comMilestone Pharmaceuticals' (MIST) Buy Rating Reaffirmed at HC WainwrightHC Wainwright restated a "buy" rating and set a $25.00 target price on shares of Milestone Pharmaceuticals in a report on Monday.October 14, 2024 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Stock, Short Interest ReportOctober 13, 2024 | benzinga.comIndividual investors account for 54% of Milestone Pharmaceuticals Inc.'s (NASDAQ:MIST) ownership, while institutions account for 46%October 9, 2024 | finance.yahoo.comShort Interest in Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Grows By 17.6%Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Get Free Report) was the target of a significant growth in short interest in September. As of September 15th, there was short interest totalling 450,000 shares, a growth of 17.6% from the August 31st total of 382,600 shares. Based on an average trading volume of 116,500 shares, the short-interest ratio is presently 3.9 days.September 30, 2024 | marketbeat.comMIST Milestone Pharmaceuticals Inc.September 28, 2024 | seekingalpha.comMilestone Pharmaceuticals to Host Investor KOL EventSeptember 24, 2024 | markets.businessinsider.comIntroducing Mighty Mist™ by DayBreak Skincare, a Premium Hypochlorous Acid Mist for All Skin TypesSeptember 17, 2024 | reuters.comMilestone Says Ji Xing Reported Positive Topline Late-stage Study Results For Etripamil In PSVTSeptember 7, 2024 | markets.businessinsider.comMilestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in ChinaSeptember 6, 2024 | globenewswire.comMilestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of DirectorsSeptember 4, 2024 | globenewswire.comMilestone® Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | finance.yahoo.comMilestone® Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024August 26, 2024 | finance.yahoo.comHC Wainwright Analysts Lower Earnings Estimates for Milestone Pharmaceuticals Inc. (NASDAQ:MIST)Milestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for shares of Milestone Pharmaceuticals in a report released on Thursday, August 22nd. HC Wainwright analyst P. Trucchio now forecasts that theAugust 26, 2024 | marketbeat.comRodman & Renshaw Initiates Coverage of Milestone Pharmaceuticals (MIST) with Buy RecommendationAugust 23, 2024 | msn.comMilestone Pharmaceuticals: A Buy Rating on CARDAMYST’s Market Potential and FDA ProgressAugust 22, 2024 | markets.businessinsider.comMilestone wins Buy at Rodman & Renshaw on potential Cardamyst approvalAugust 22, 2024 | msn.comHC Wainwright Reaffirms Buy Rating for Milestone Pharmaceuticals (NASDAQ:MIST)HC Wainwright reissued a "buy" rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Thursday.August 22, 2024 | marketbeat.comMilestone Pharmaceuticals (NASDAQ:MIST) Coverage Initiated at Rodman & RenshawRodman & Renshaw started coverage on shares of Milestone Pharmaceuticals in a research note on Thursday. They issued a "buy" rating and a $9.00 price objective on the stock.August 22, 2024 | marketbeat.comBuy Rating Affirmed for Milestone Pharmaceuticals on Etripamil’s Market Potential and Solid Financial FootingAugust 13, 2024 | markets.businessinsider.comMilestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate UpdateAugust 8, 2024 | globenewswire.com4 Stocks Under $5 To Buy NowAugust 8, 2024 | 247wallst.comMilestone Pharmaceuticals Inc (MIST)July 31, 2024 | investing.comMilestone® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology ConferenceJuly 31, 2024 | finance.yahoo.comMilestone Pharmaceuticals to Host KOL Event for Investors “Learnings from the Field: Expert Perspectives on PSVT in the Community Setting” on June 20, 2024June 12, 2024 | globenewswire.comQ1 2025 Earnings Estimate for Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Issued By HC WainwrightMilestone Pharmaceuticals Inc. (NASDAQ:MIST - Free Report) - HC Wainwright issued their Q1 2025 EPS estimates for shares of Milestone Pharmaceuticals in a research note issued to investors on Thursday, May 30th. HC Wainwright analyst P. Trucchio forecasts that the company will earn ($0.15) per shJune 3, 2024 | marketbeat.comMilestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare ConferenceMay 31, 2024 | globenewswire.comMilestone Pharmaceuticals (NASDAQ:MIST) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and set a $25.00 price target on shares of Milestone Pharmaceuticals in a report on Thursday.May 30, 2024 | marketbeat.comMilestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYSTMay 29, 2024 | finanznachrichten.de Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address MIST Media Mentions By Week MIST Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MIST News Sentiment▼0.630.60▲Average Medical News Sentiment MIST News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MIST Articles This Week▼31▲MIST Articles Average Week Get Milestone Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MIST and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KALV News PROK News ABVX News ORGO News CMPX News AKBA News PRTC News ALT News CDXC News KMDA News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MIST) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Milestone Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Milestone Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MIST Stock Alerts